By careful selection and experimental design, fragments can provide very useful starting points for medicinal chemistry-driven programmes, leading to tailor-made, selective molecules with highly favourable physico-chemical and ADMET properties

[1]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[2]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[3]  Andrew R Leach,et al.  Fragment screening: an introduction. , 2006, Molecular bioSystems.

[4]  Glyn Williams,et al.  Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.

[5]  Walter Huber,et al.  A new strategy for improved secondary screening and lead optimization using high‐resolution SPR characterization of compound–target interactions , 2005, Journal of molecular recognition : JMR.

[6]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[7]  P. Hajduk,et al.  Privileged molecules for protein binding identified from NMR-based screening. , 2000, Journal of medicinal chemistry.

[8]  Zartler Er,et al.  Protein NMR-based screening in drug discovery. , 2006 .

[9]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[10]  Sid Topiol,et al.  Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. , 2008, Bioorganic & medicinal chemistry letters.

[11]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[12]  Karl Edman,et al.  Novel prostaglandin D synthase inhibitors generated by fragment-based drug design. , 2008, Journal of medicinal chemistry.

[13]  T. Sixma,et al.  Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors , 2001, Nature.

[14]  C. Lindsley,et al.  Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5). , 2005, Current topics in medicinal chemistry.

[15]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[16]  B. Kobilka,et al.  New G-protein-coupled receptor crystal structures: insights and limitations. , 2008, Trends in pharmacological sciences.

[17]  Tudor I. Oprea,et al.  Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.

[18]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.